Zimbabwe has turned down a significant American health deal valued at $367m (£272m) spanning five years because of the United States' insistence on confidential information.
The decision became public following a official document from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesman has since clarified that the US was requesting genetic material for research and commercial gain while was unwilling to share the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for continued talks to find a agreement agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This development follows a comparable case in Kenya, where a high court suspended a similar deal with the US after legal challenges were raised about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
According to statements, Sixteen African countries have so far agreed to these new health pacts, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"In essence, our nation would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our citizens if a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining systems previously set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This framework is intended to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We encourage continued discussions with our American counterparts on how subsequent co-operation might be structured in a manner that respects the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks should continue given that much of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it added.
The situation emphasises the complex tensions between accepting vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.